Shots:
- The US FDA has received 510(k) Application for MosaiQ AiPlex Multiplex Microarray to improve & accelerate diagnosis of celiac disease
- MosaiQ simplifies serological evaluation with syndromic approach by combining IgA & IgG isotypes to detect IgA deficiency & measure anti-tTG as well as anti-DGP (AU/mL) using just 20 μL of sample in single step, while the CD microassay incl. 5 markers in panel per pts incl. most auto-Abs for detection
- MosaiQ allows a simple workflow with rapid results, detecting ~425 celiac disease markers/hr. with RFID-tagged reagents & loaders accelerating the processes to reduce time, consumables, & errors while improving calibration, quality control, & lab efficiency
Ref: AliveDx | Image: AliveDx
Related News:- Senseonics Seeks the CE Mark Approval for Eversense 365 System
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
